The Impact of COVID-19 on Lung Cancer Incidence in England
CHEST · 2023
DOI: 10.1016/j.chest.2023.01.008 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift CHEST, 2023. Verfasst von Savannah Gysling und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lifespan and Population Health, University of Nottingham, Nottingham, England. Electronic address: s.gysling@nhs.net. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, COVID-19. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: The COVID-19 pandemic has caused significant disruption to health-care services and delivery worldwide. The impact of the pandemic and associated national lockdowns on lung cancer incidence in England have yet to be assessed. RESEARCH QUESTION: What was the impact of the first year of the COVID-19 pandemic on the incidence and presentation of lung cancer in England? STUDY DESIGN AND METHODS: In this retrospective observational study, incidence rates for lung cancer were calculated from The National Lung Cancer Audit Rapid Cancer Registration Datasets for 2019 and 2020, using midyear population estimates from the Office of National Statistics as the denominators. Rates were compared using Poisson regression according to time points related to national lockdowns in 2020. RESULTS: Sixty-four thousand four hundred fifty-seven patients received a diagnosis of lung cancer across 2019 (n = 33,088) and 2020 (n = 31,369). During the first national lockdown, a 26% reduction in lung cancer incidence was observed compared with the equivalent calendar period of 2019 (adjusted incidence rate ratio [IRR], 0.74; 95% CI, 0.71-0.78). This included a 23% reduction in non-small cell lung cancer (adjusted IRR, 0.77; 95% CI, 0.74-0.81) and a 45% reduction in small cell lung cancer (adjusted IRR, 0.55; 95% CI, 0.46-0.65) incidence. Thereafter, incidence rates almost recovered to baseline, without overcompensation (adjusted IRR, 0.96; 95% CI, 0.94-0.98). INTERPRETATION: The incidence rates of lung cancer in England fell significantly by 26% during the first national lockdown in 2020 and did not compensate later in the year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lifespan and Population Health, University of Nottingham, Nottingham, England. Electronic address: s.gysling@nhs.net.
- Lifespan and Population Health, University of Nottingham, Nottingham, England.
- Department of Thoracic Surgery, University Hospitals Bristol and Weston NHS Trust, Bristol, England.
- Department of Clinical Oncology, Barts Health NHS Trust, London, England.
- Lungs for Living Research Centre, UCL Respiratory, University College London, London, England; Department of Thoracic Medicine, University College London Hospitals NHS Trust, London, England.
- Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, England.
Zitieren
APA
Gysling, S., Morgan, H., Ifesemen, O. S., West, D., Conibear, J., Navani, N., O'Dowd, E. L., Baldwin, D. R., Humes, D., & Hubbard, R. (2023). The Impact of COVID-19 on Lung Cancer Incidence in England. CHEST. https://doi.org/10.1016/j.chest.2023.01.008
Vancouver
Gysling S, Morgan H, Ifesemen OS, West D, Conibear J, Navani N, et al. The Impact of COVID-19 on Lung Cancer Incidence in England. CHEST. 2023. doi:10.1016/j.chest.2023.01.008
BibTeX
@article{Gysling2023,
author = {Gysling, Savannah and Morgan, Helen and Ifesemen, Onosi Sylvia and West, Douglas and Conibear, John and Navani, Neal and O'Dowd, Emma Louise and Baldwin, David R and Humes, David and Hubbard, Richard},
title = {The Impact of COVID-19 on Lung Cancer Incidence in England},
journal = {CHEST},
year = {2023},
doi = {10.1016/j.chest.2023.01.008}
}
EUVIMED